|
Canada-0-Searchers of Records 公司名錄
|
公司新聞:
- Current state of biologics in treating eosinophilic esophagitis
Eosinophilic esophagitis (EoE) is a chronic, allergen-mediated, eosinophil-predominant, type 2 inflammatory disease that progresses to fibrostenosis of the esophagus if left untreated This review focuses on biologics therapy in EoE
- Biologics for eosinophilic oesophagitis: a systematic review . . .
Lucendo AJ, Molina-Infante J, Arias Á, et al Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults United European Gastroenterol J 2017;5(3):335–358 doi: 10 1177 2050640616689525
- Biologics in the Treatment of Eosinophilic Esophagitis: Ready . . .
Eosinophilic esophagitis (EoE) is a chronic disease mediated by environmental allergens and type 2 immune inflammation, which causes significant symptoms including dysphagia and food impaction 1,2 The incidence and prevalence of EoE are rising and untreated disease can lead to significant esophageal stenosis 2,3 Standard treatments include proton-pump inhibitors (PPIs), swallowed topical
- Biologics in Eosinophilic Esophagitis — Ready for Prime Time?
In Western countries, the disease currently affects approximately 1 in 3000 persons 3 The most common symptom of eosinophilic esophagitis in adults is dysphagia with solid food intake, often
- Biologics in eosinophilic esophagitis - PubMed
Purpose of review: Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the oesophagus whose incidence is on the rise Despite maximal use of guideline-based therapies including food elimination diets and steroids, many patients remain symptomatic
|
|